{"classes":[{"categories":[{"measurements":[{"comment":"Standard deviation was not derived as only one participant was evaluated.","groupId":"OG000","spread":"NA","value":"-8.0"},{"comment":"Standard deviation was not derived as only one participant was evaluated.","groupId":"OG001","spread":"NA","value":"-1.0"},{"comment":"Standard deviation was not derived as only one participant was evaluated.","groupId":"OG003","spread":"NA","value":"-30.0"},{"comment":"Standard deviation was not derived as only one participant was evaluated.","groupId":"OG005","spread":"NA","value":"35.0"},{"comment":"Standard deviation was not derived as only one participant was evaluated.","groupId":"OG006","spread":"NA","value":"-14.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"}],"units":"Participants"}],"description":"Change in AXL expression (total humor H-score in membrane or cytoplasm) from Baseline to EOT visit for the expansion part is reported. The H-score captures both the intensity and proportion of AXL positive tumor cells and was defined by the formula: H-score = (1 × % 1+ tumor cells) + (2 × % 2+ tumor cells) + (3 × % 3+ tumor cells); where '1+' indicates weak staining intensity, '2+' indicates medium staining intensity, and '3+' indicates strong staining intensity. The H-score values ranges from 0 to 300. Lower H-scores represent lower AXL expression in the tumor sample, while higher scores represent stronger AXL expression in the tumor samples.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with advanced and/or metastatic NSCLC with classical sensitizing EGFR mutations and/or EGFR mutations targeted by third-generation tyrosine kinase inhibitors) received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG000","title":"Expansion Part Cohort 1: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic melanoma with BRAF V600 mutation received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG001","title":"Expansion Part Cohort 3: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic melanoma with BRAF V600 wild type received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG002","title":"Expansion Part Cohort 4: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic sarcoma received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG003","title":"Expansion Part Cohort 5: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic solid tumors (excluding NSCLC, melanoma, sarcoma, and ovarian cancer unless having a known AXL gene amplification) received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"OG004","title":"Expansion Part Cohort 6: Enapotamab Vedotin 1.0 mg/kg 3Q4W"},{"description":"Participants with advanced and/or metastatic platinum-resistant ovarian cancer received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG005","title":"Expansion Part Cohort 7: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG006","title":"Expansion Part Cohort 2: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 1.8 mg/kg 1Q3W until the end of treatment.","id":"OG007","title":"Expansion Part Cohort 2: Enapotamab Vedotin 1.8 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"OG008","title":"Expansion Part Cohort 8: Enapotamab Vedotin 1.0 mg/kg 3Q4W"}],"paramType":"MEAN","populationDescription":"The full analysis set included all participants who received at least 1 dose of enapotamab vedotin. Participants were classified according to first dose received in the expansion part. Participants who had tumor H-scores in membrane or cytoplasm assessed at Baseline and at the end of treatment visit were evaluated for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline (Study Days -21 to 1) and EOT visit (Day 1100)","title":"Change in AXL Expression (Total Tumor H-score) From Baseline to EOT Visit for Expansion Part","type":"SECONDARY","unitOfMeasure":"Score on a scale"}